SCHEMBL3129016

SCHEMBL3129016

CCOc1ccc(N(Cc2cccnc2)c2cccc(C(=O)O)c2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
GRM2 Q14416 3/20 0.47
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
MRGPRX4 Q96LA9 3/20 0.46
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
ALDH1A1 P00352 3/20 0.44
USP2 O75604 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
QPCT Q16769 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186765 0.96 GRM2 (0.47) TSHRGRM2MAPTMRGPRX4PDE4A
SCHEMBL4190655 0.93 ALDH1A1 (0.50) TSHRGRM2MAPTMRGPRX4PDE4A
SCHEMBL3129550 0.92 TSHR (0.52) TSHRGRM2NPC1MAPTPDE4A
SCHEMBL3127770 0.90 TSHR (0.52) TSHRNPC1MAPTMRGPRX4ALDH1A1
SCHEMBL4190639 0.89 GRM2 (0.48) GRM2MAPTMRGPRX4PDE4APDE4B
SCHEMBL4193526 0.88 L3MBTL1 (0.48) TSHRGRM2NPC1MAPTPDE4A
SCHEMBL3205165 0.88 NPC1 (0.43) GRM2NPC1MAPTPDE4APDE4B
SCHEMBL4198518 0.87 GRM2 (0.47) TSHRGRM2MAPTPDE4APDE4B
SCHEMBL3132076 0.87 GRM2 (0.44) GRM2MAPTMRGPRX4PDE4APDE4B
SCHEMBL3200102 0.87 PDE4B (0.45) GRM2MAPTMRGPRX4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B TSHR 1908/4885GRM2 3498/4885NPC1 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.